Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak

Seung Heon Lee, Woo Jin Lew, Hee Jin Kim, Hyun Kyung Lee, Young Min Lee, Chong Hee Cho, Eun Joo Lee, Dong Yeol Lee, Sung Weon Ryu, Soo Yeon Oh, Sin Ok Kim, Tae Sun Shim

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Even though some studies have reported the results of serial interferon-gamma release assays (IGRAs) during isoniazid prophylactic treatment, serial results have not been reported after rifampicin prophylaxis. A contact investigation was conducted after a tuberculosis (TB) outbreak in an accommodation facility. The tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-GIT) test were performed in 214 contacts with normal chest radiographs. Rifampicin prophylaxis was initiated in TST+/QFT-GIT+ subjects, and the QFT-GIT test was repeated upon completion of 4 months of rifampicin treatment. Among the 214 contacts, the TST and QFT-GIT test results were positive in 67.7% and 56.7%, respectively, and the agreement between the two tests was fair-to-good (78.3%, kappa = 0.55, p < 0.001). The QFT-GIT test was positive in 77% (97/126) of contacts with positive TST results. Rifampicin prophylaxis was completed in 81 subjects with good compliance. Among 74 subjects with valid serial QFT-GIT test results, IFN-γ levels decreased in 97.3% (72/74) of the subjects and QFT-GIT test reversion (positive to negative) was achieved in 31 subjects (41.9%). Subjects without QFT-GIT test reversion had a significantly higher baseline TST induration sizes (18.3 ± 4.8 vs. 14.9 ± 3.4 mm, p < 0.01) and IFN-γ levels (18.6 ± 17.9 vs. 3.2 ± 7.5 IU/mL, p < 0.01) than the subjects with QFT-GIT test reversion. Thus, IGRAs may be useful in evaluating the therapeutic response to rifampicin prophylaxis in TB contacts. However, considering that this was not a controlled study, a prospective controlled study is needed to determine whether rifampicin prophylaxis truly affects QFT-GIT reversion.

Original languageEnglish
Pages (from-to)448-453
Number of pages6
JournalRespiratory Medicine
Volume104
Issue number3
DOIs
Publication statusPublished - 2010 Mar 1
Externally publishedYes

Fingerprint

Interferon-gamma Release Tests
Rifampin
Gold
Disease Outbreaks
Tuberculosis
Tuberculin Test
Skin Tests
Isoniazid
Thorax

Keywords

  • Interferon-gamma release assay
  • Rifampicin prophylaxis
  • Serial testing
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. / Lee, Seung Heon; Lew, Woo Jin; Kim, Hee Jin; Lee, Hyun Kyung; Lee, Young Min; Cho, Chong Hee; Lee, Eun Joo; Lee, Dong Yeol; Ryu, Sung Weon; Oh, Soo Yeon; Kim, Sin Ok; Shim, Tae Sun.

In: Respiratory Medicine, Vol. 104, No. 3, 01.03.2010, p. 448-453.

Research output: Contribution to journalArticle

Lee, SH, Lew, WJ, Kim, HJ, Lee, HK, Lee, YM, Cho, CH, Lee, EJ, Lee, DY, Ryu, SW, Oh, SY, Kim, SO & Shim, TS 2010, 'Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak', Respiratory Medicine, vol. 104, no. 3, pp. 448-453. https://doi.org/10.1016/j.rmed.2009.10.006
Lee, Seung Heon ; Lew, Woo Jin ; Kim, Hee Jin ; Lee, Hyun Kyung ; Lee, Young Min ; Cho, Chong Hee ; Lee, Eun Joo ; Lee, Dong Yeol ; Ryu, Sung Weon ; Oh, Soo Yeon ; Kim, Sin Ok ; Shim, Tae Sun. / Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. In: Respiratory Medicine. 2010 ; Vol. 104, No. 3. pp. 448-453.
@article{6b8a5125c1964f44b2faf161612cfcfb,
title = "Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak",
abstract = "Even though some studies have reported the results of serial interferon-gamma release assays (IGRAs) during isoniazid prophylactic treatment, serial results have not been reported after rifampicin prophylaxis. A contact investigation was conducted after a tuberculosis (TB) outbreak in an accommodation facility. The tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-GIT) test were performed in 214 contacts with normal chest radiographs. Rifampicin prophylaxis was initiated in TST+/QFT-GIT+ subjects, and the QFT-GIT test was repeated upon completion of 4 months of rifampicin treatment. Among the 214 contacts, the TST and QFT-GIT test results were positive in 67.7{\%} and 56.7{\%}, respectively, and the agreement between the two tests was fair-to-good (78.3{\%}, kappa = 0.55, p < 0.001). The QFT-GIT test was positive in 77{\%} (97/126) of contacts with positive TST results. Rifampicin prophylaxis was completed in 81 subjects with good compliance. Among 74 subjects with valid serial QFT-GIT test results, IFN-γ levels decreased in 97.3{\%} (72/74) of the subjects and QFT-GIT test reversion (positive to negative) was achieved in 31 subjects (41.9{\%}). Subjects without QFT-GIT test reversion had a significantly higher baseline TST induration sizes (18.3 ± 4.8 vs. 14.9 ± 3.4 mm, p < 0.01) and IFN-γ levels (18.6 ± 17.9 vs. 3.2 ± 7.5 IU/mL, p < 0.01) than the subjects with QFT-GIT test reversion. Thus, IGRAs may be useful in evaluating the therapeutic response to rifampicin prophylaxis in TB contacts. However, considering that this was not a controlled study, a prospective controlled study is needed to determine whether rifampicin prophylaxis truly affects QFT-GIT reversion.",
keywords = "Interferon-gamma release assay, Rifampicin prophylaxis, Serial testing, Tuberculosis",
author = "Lee, {Seung Heon} and Lew, {Woo Jin} and Kim, {Hee Jin} and Lee, {Hyun Kyung} and Lee, {Young Min} and Cho, {Chong Hee} and Lee, {Eun Joo} and Lee, {Dong Yeol} and Ryu, {Sung Weon} and Oh, {Soo Yeon} and Kim, {Sin Ok} and Shim, {Tae Sun}",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.rmed.2009.10.006",
language = "English",
volume = "104",
pages = "448--453",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak

AU - Lee, Seung Heon

AU - Lew, Woo Jin

AU - Kim, Hee Jin

AU - Lee, Hyun Kyung

AU - Lee, Young Min

AU - Cho, Chong Hee

AU - Lee, Eun Joo

AU - Lee, Dong Yeol

AU - Ryu, Sung Weon

AU - Oh, Soo Yeon

AU - Kim, Sin Ok

AU - Shim, Tae Sun

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Even though some studies have reported the results of serial interferon-gamma release assays (IGRAs) during isoniazid prophylactic treatment, serial results have not been reported after rifampicin prophylaxis. A contact investigation was conducted after a tuberculosis (TB) outbreak in an accommodation facility. The tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-GIT) test were performed in 214 contacts with normal chest radiographs. Rifampicin prophylaxis was initiated in TST+/QFT-GIT+ subjects, and the QFT-GIT test was repeated upon completion of 4 months of rifampicin treatment. Among the 214 contacts, the TST and QFT-GIT test results were positive in 67.7% and 56.7%, respectively, and the agreement between the two tests was fair-to-good (78.3%, kappa = 0.55, p < 0.001). The QFT-GIT test was positive in 77% (97/126) of contacts with positive TST results. Rifampicin prophylaxis was completed in 81 subjects with good compliance. Among 74 subjects with valid serial QFT-GIT test results, IFN-γ levels decreased in 97.3% (72/74) of the subjects and QFT-GIT test reversion (positive to negative) was achieved in 31 subjects (41.9%). Subjects without QFT-GIT test reversion had a significantly higher baseline TST induration sizes (18.3 ± 4.8 vs. 14.9 ± 3.4 mm, p < 0.01) and IFN-γ levels (18.6 ± 17.9 vs. 3.2 ± 7.5 IU/mL, p < 0.01) than the subjects with QFT-GIT test reversion. Thus, IGRAs may be useful in evaluating the therapeutic response to rifampicin prophylaxis in TB contacts. However, considering that this was not a controlled study, a prospective controlled study is needed to determine whether rifampicin prophylaxis truly affects QFT-GIT reversion.

AB - Even though some studies have reported the results of serial interferon-gamma release assays (IGRAs) during isoniazid prophylactic treatment, serial results have not been reported after rifampicin prophylaxis. A contact investigation was conducted after a tuberculosis (TB) outbreak in an accommodation facility. The tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-GIT) test were performed in 214 contacts with normal chest radiographs. Rifampicin prophylaxis was initiated in TST+/QFT-GIT+ subjects, and the QFT-GIT test was repeated upon completion of 4 months of rifampicin treatment. Among the 214 contacts, the TST and QFT-GIT test results were positive in 67.7% and 56.7%, respectively, and the agreement between the two tests was fair-to-good (78.3%, kappa = 0.55, p < 0.001). The QFT-GIT test was positive in 77% (97/126) of contacts with positive TST results. Rifampicin prophylaxis was completed in 81 subjects with good compliance. Among 74 subjects with valid serial QFT-GIT test results, IFN-γ levels decreased in 97.3% (72/74) of the subjects and QFT-GIT test reversion (positive to negative) was achieved in 31 subjects (41.9%). Subjects without QFT-GIT test reversion had a significantly higher baseline TST induration sizes (18.3 ± 4.8 vs. 14.9 ± 3.4 mm, p < 0.01) and IFN-γ levels (18.6 ± 17.9 vs. 3.2 ± 7.5 IU/mL, p < 0.01) than the subjects with QFT-GIT test reversion. Thus, IGRAs may be useful in evaluating the therapeutic response to rifampicin prophylaxis in TB contacts. However, considering that this was not a controlled study, a prospective controlled study is needed to determine whether rifampicin prophylaxis truly affects QFT-GIT reversion.

KW - Interferon-gamma release assay

KW - Rifampicin prophylaxis

KW - Serial testing

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=76549135610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549135610&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2009.10.006

DO - 10.1016/j.rmed.2009.10.006

M3 - Article

VL - 104

SP - 448

EP - 453

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 3

ER -